in this issue
Regions :: North America :: U.S.
Sun Pharma and Lupin receive FDA approvals for generic Cymbalta
December 12, 2013 | Natasha Alperowicz
Sun Pharmaceutical Industries (Mumbai) and Lupin (Mumbai), two leading pharma producers for the global markets, announced today that their US subsidiaries have gained FDA approvals for duloxetine hydrochloride delayed release drug, the generic version of the antidepressant Cymbalta. Cymbalta delayed-release capsule 20, 30 and 60 mg is an Eli Lilly product with last year’s sales in the United States approaching $5.5 billion. Sun Pharma in the year ended 31 March 2013 reported sales of $2.1 billion of which $1.1 billion were in the US...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee